SOURCE BIOSCIENCE UK LIMITED

Get an alert when SOURCE BIOSCIENCE UK LIMITED files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2027-01-23 (in 8mo)

Last made up 2026-01-09

Watchouts

None on the register

Cash

£2M

+22.5% vs 2023

Net assets

£23M

+8.6% vs 2023

Employees

120

-6.3% vs 2023

Profit before tax

£2M

-37.3% vs 2023

Name history

Renamed 5 times since incorporation

SOURCE BIOSCIENCE UK LIMITED 2009-02-19 → present
MEDICAL SOLUTIONS (NOTTINGHAM) LIMITED 2007-07-12 → 2009-02-19
PATHLORE LTD 2001-04-19 → 2007-07-12
ADVANCED DIAGNOSTIC SOLUTIONS LIMITED 2000-11-27 → 2001-04-19
ADVANCED DIAGNOSTIC LABORATORIES LIMITED 2000-10-24 → 2000-11-27
ANGLIA TELECOMMUNICATIONS LIMITED 2000-09-26 → 2000-10-24

Net assets

2-year trend · vs Industrials median

SOURCE BIOSCIENCE UK LIMITED·Industrials median · n=6236

Accounts

2-year trend · latest reflected 2024-12-31

Metric	2023-12-31	2024-12-31
Turnover	£23,539,000	£27,957,000
Operating profit	£2,658,000	£1,649,000
Profit before tax	£2,635,000	£1,652,000
Net profit	£2,551,000	£1,698,000
Cash	£1,835,000	£2,247,000
Total assets less current liabilities	£23,255,000	£24,743,000
Net assets	£20,935,000	£22,738,000
Equity	£20,935,000	£22,738,000
Average employees	128	120
Wages	£5,962,000	£6,096,000

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio	2023-12-31	2024-12-31
Operating margin	11.3%	5.9%
Net margin	10.8%	6.1%
Return on capital employed	11.4%	6.7%
Gearing (liabilities / total assets)	28.1%	46.4%
Current ratio	3.87x	2.09x
Interest cover	75.94x	31.71x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis: FRS 102
Reporting scope: Standalone (parent only)
Auditor: RSM UK Audit LLP
Audit opinion: Unqualified (clean)
Going concern: Affirmed
“Having considered the future forecasts and availability of financing to the wider group, the directors have a reasonable expectation that the company has adequate resources to continue operating for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.”

Significant events

“During 2024, the Company recorded significant revenue and underlying EBITDA growth, mainly due to the success of the Histopathology Diagnostics business unit and the continued conversion to digital pathology.”
“In the current year, the company benefited from a release of inter-company balances of £0.2 million (2023: £2.4 million).”
“The recent Post Balance sheet acquisition will assist the company with some focused diversification and additional opportunities in a new market.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

2 active · 28 resigned

Name	Role	Appointed	Born	Nationality
BARLOW, Amanda Louise	Director	2023-09-27	Aug 1973	British
LECOQUE, Jay Charles	Director	2017-04-27	Nov 1962	American

Show 28 resigned officers

Name	Role	Appointed	Resigned
ASH, Nicholas Watson, Dr	Secretary	2006-08-31	2017-05-12
ASTLE, Michael John	Secretary	2017-05-12	2017-10-05
JOHNSTON, Neil Gerard, Dr	Secretary	2005-01-19	2006-08-31
LONGSTAFFE, Andrew David	Secretary	2003-08-19	2005-01-19
LONGSTAFFE, Andrew David	Secretary	2001-01-25	2001-06-26
MINSHALL, Mark Richard	Secretary	2001-06-26	2003-08-19
HAMMOND SUDDARDS SECRETARIES LIMITED	Corporate Secretary	2000-10-16	2001-09-01
RUTLAND SECRETARIES LIMITED	Corporate Nominee Secretary	2000-09-26	2000-10-16
AGNEW, James Douglas	Director	2017-04-27	2017-05-12
ASH, Nicholas Watson, Dr	Director	2006-08-31	2017-05-12
BAKEWELL, Robert	Director	2012-08-21	2014-09-04
CHISHOLM, Iain Macdonald	Director	2017-04-27	2018-01-02
ELLIS, Ian Ogilvie, Professor	Director	2001-02-13	2007-09-11
GREEN, Charles Alexander	Director	2001-01-25	2006-08-31
JOHNSTON, Neil Gerard, Dr	Director	2006-08-31	2007-01-31
KIRKHAM, David Michael	Director	2021-06-16	2022-09-26
LEAVES, Nicholas Ivor, Dr	Director	2008-10-01	2017-05-12
LONGSTAFFE, Andrew David	Director	2001-01-25	2005-01-19
METCALFE, Timothy Charles	Director	2014-09-04	2017-05-12
MINSHALL, Mark Richard	Director	2001-01-25	2003-11-10
NOLAN, Trevor Frank	Director	2018-01-09	2020-02-28
RATCLIFFE, Anthony James	Director	2020-11-17	2023-09-27
ROBERTS, Gareth Gwyn, Professor Sir	Director	2001-01-25	2007-02-01
TWOSE, Trevor Martin, Doctor	Director	2001-02-13	2002-02-08
WELLS, Michael, Professor	Director	2001-05-25	2005-01-19
WHEATCROFT, Russell Steven	Director	2017-04-27	2021-06-15
HSE DIRECTORS LIMITED	Corporate Director	2000-10-16	2001-01-25
RUTLAND DIRECTORS LIMITED	Corporate Nominee Director	2000-09-26	2000-10-16

Ownership

Persons with significant control

Name	Kind	Nature of control	Notified	Status
Source Bioscience Limited	Corporate entity	Shares 75–100%, Voting 75–100%, Appoints directors	2016-09-26	Active

Filing timeline

Last 20 of 158 total filings

Date	Type	Category	Description
2026-01-22	CS01	confirmation-statement	Confirmation statement with updates	PDF
2025-08-06	AA	accounts	Accounts with accounts type full
2025-01-13	CS01	confirmation-statement	Confirmation statement with updates	PDF
2024-10-12	AA	accounts	Accounts with accounts type full
2024-01-09	CS01	confirmation-statement	Confirmation statement with updates	PDF
2023-10-02	TM01	officers	Termination director company with name termination date	PDF
2023-10-02	AP01	officers	Appoint person director company with name date	PDF
2023-06-22	AA	accounts	Accounts with accounts type full
2023-01-09	CS01	confirmation-statement	Confirmation statement with updates	PDF
2022-11-24	MR01	mortgage	Mortgage create with deed with charge number charge creation date	PDF
2022-09-26	TM01	officers	Termination director company with name termination date	PDF
2022-09-05	CS01	confirmation-statement	Confirmation statement with updates	PDF
2022-08-01	AA	accounts	Accounts with accounts type full
2021-09-17	AA	accounts	Accounts with accounts type full
2021-09-12	CS01	confirmation-statement	Confirmation statement with updates	PDF
2021-08-10	CH01	officers	Change person director company with change date	PDF
2021-06-17	AP01	officers	Appoint person director company with name date	PDF
2021-06-15	TM01	officers	Termination director company with name termination date	PDF
2021-02-24	MR04	mortgage	Mortgage satisfy charge full
2021-02-19	MR04	mortgage	Mortgage satisfy charge full

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings: 2
Capital events: 0
Officers appointed: 0
Officers resigned: 0

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Turnover

+18.8%

£23,539,000 £27,957,000
Cash

+22.5%

£1,835,000 £2,247,000
Net assets

+8.6%

£20,935,000 £22,738,000
Employees

-6.3%

128 120
Operating profit

-38%

£2,658,000 £1,649,000
Profit before tax

-37.3%

£2,635,000 £1,652,000
Wages

+2.2%

£5,962,000 £6,096,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Official Companies House page